中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

慢性乙型肝炎患者血小板指数与肝组织病理的关系

陈念 黄卫娥 苏明华 江建宁

引用本文:
Citation:

慢性乙型肝炎患者血小板指数与肝组织病理的关系

DOI: 10.3969/j.issn.1001-5256.2016.01.019
基金项目: 

广西自然科学青年基金资助项目(0832037); 广西自然科学基金(0832117); 广西卫生厅自筹课题(z2014410); 柳州市人民医院院内课题(lry201306); 

详细信息
  • 中图分类号: R512.62

Correlation between platelet indices and liver pathological staging: an analysis of 167 patients with chronic hepatitis B

Research funding: 

 

  • 摘要: 目的研究慢性乙型肝炎(CHB)患者AST/血小板(PLT)比值(APRI)及ALT/PLT比值(BPRI)与肝组织病理改变的关系。方法收集2004年2月-2014年2月于柳州市人民医院行肝活组织检查的CHB患者167例,检测患者的血常规及肝功能,将APRI、BPRI与肝组织病理进行分析。计量资料组间比较采用Mann-Whitney U检验,分析评价采用受试者工作特征(ROC)曲线法。结果在肝组织病理炎症分级G0、G1、G2、G3、G4各组中,APRI进行比较,G1与G2、G3差异均具有统计学意义(P值均<0.05);G01组与G24组的APRI比较差异有统计学意义(P<0.05)。各组BPRI进行比较,G0与G4、G1与G2差异均有统计学意义(P值均<0.05)。G01与G24进行比较,BPRI差异有统计学意义(P<0.05)。在S0、S1、S2、S3、S4各组中,APRI、BPRI两两比较,S2与S3差异均有统计学意义(P值均<0.05)。APRI、BPRI预测肝组织...

     

  • [1]CHANG MH.Hepatitis B virus infection[J].Semin Fetal Neonatal Med,2007,12(3):160-167.
    [2]ZHANG ZH,YANG SW.Dynamic changes of serum markers in patients with chronic hepatitis B[J].Int J Virol,2015,22(4):270-273.(in Chinese)张正怀,杨树伟.慢性乙型肝炎患者两对半指标变化监测分析[J].国际病毒学杂志,2015,22(4):270-273.
    [3]SUN DC,CHEN L,WU ZY,et al.Diagnosis and management of the hepatitis B reactivation in patients receiving cytotoxic chemotherapy[J].Chin J Clin Pharmacol Ther,2014,19(5):584-590.(in Chinese)孙德聪,陈丽,吴志勇,等.化疗相关乙肝病毒再激活的诊治现状[J].中国临床药理学与治疗学,2014,19(5):584-590.
    [4] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B(2010 version)[J].J Clin Hepatol,2011,27(1):Ⅰ-ⅩⅥ.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].临床肝胆病杂志,2011,27(1):Ⅰ-ⅩⅥ.
    [5]WAI CT,GREENSON JK,FONTANA RJ,et al.A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C[J].Hepatology,2003,38(2):518-526.
    [6]Chinese Society of Infectious Diseases and Parasitology,Chinese Society of Hepatology,Chinese Medical Association.Prevention and treatment of viral hepatitis[J].Chin J Hepatol,2000,8(6):324-329.(in Chinese)中华医学会传染病与寄生虫病学分会、肝病学分会.病毒性肝炎防治方案[J].中华肝脏病杂志,2000,8(6):324-329.
    [7]MA JJ,FENG LY,FENG ZJ,et al.Relationship of liver pathology and clinical data of HBV-infected patients with normal or mildly abnormal alanine aminotransferase level[J].Chin Gen Pract,2013,16(5B):1603-1606.(in Chinese)马俊骥,冯丽英,冯志杰,等.丙氨酸氨基转移酶正常或轻度异常乙型肝炎病毒感染者肝病理与临床关系研究[J].中国全科医学,2013,16(5B):1603-1606.
    [8]BOURLIERE M,PENARANDA G,OUZAN D,et al.Optimized stepwise combination algorithms of non-invasive liver fibrosis scores including Hepascore in hepatitis C virus patients[J].Aliment Pharmacol Ther,2008,28(4):458-467.
    [9]SHAHEEN AA,MYERS RP.Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis:a systematic review[J].Hepatology,2007,46(3):912-921.
    [10]SEBASTIANI G,CASTERA L,HALFON P,et al.The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers:an international study of 2411 cases[J].Aliment Pharmacol Ther,2011,34(10):1202-1216.
    [11]PAN JJ,SUN QL.Clinical utility of aspartate aminotransferase to platelet ratio index in chronic hepatitis B virus infection with transaminase less than two times of upper limits of normal[J].Chin J Infect Dis,2014,32(1):48-51.(in Chinese)潘劲劲,孙秋林.天冬氨酸转氨酶与血小板比值在转氨酶正常值上限两倍以下慢性乙型肝炎病毒感染者中的临床应用评价[J].中华传染病杂志,2014,32(1):48-51.
    [12]FENG F,MA SM,CHEN F,et al.Diagnostic value of LSM combined with APRI for liver fibrosis due to chronic hepatitis B[J].J Clin Hepatol,2013,29(10):752-755.(in Chinese)冯菲,马苏美,陈飞,等.肝硬变检测联合APRI指数对慢性乙型肝炎患者肝纤维化程度的诊断价值[J].临床肝胆病杂志,2013,29(10):752-755.
    [13]ZHU X,WANG LC,CHEN EQ,et al.Prospective evaluation of Fibro Scan for the diagnosis of hepatic fibrosis compared with liver biopsy/AST platelet ratio index and FIB-4 in patients with chronic HBV infection[J].Dig Dis Sci,2011,56(9):2742-2749.
    [14]CHOU YC,YU MW,WU CF,et al.Temporal relationship between hepatitis B virus enhancerⅡ/basal core promoter sequence variation and risk of hepatocellular carcinoma[J].Gut,2008,57(1):91-97.
  • 加载中
计量
  • 文章访问数:  2510
  • HTML全文浏览量:  21
  • PDF下载量:  498
  • 被引次数: 0
出版历程
  • 收稿日期:  2015-05-05
  • 出版日期:  2016-01-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回